Pretherapy predictive immunomodulation of NK cell activity and expression of activating and inhibitory receptors in stage IV melanoma patients

• DOI: 10.1200/jco.2006.24.18_suppl.12514
• Publication Date: 2020-03-09T19:51:07Z
• Authors: G. Konjevic; K. Mirjacic; A. Radovanovic; V. Jovic; N. Babovic; I. Spuzic
• Keywords: NKG2D; Receptor expression; Biological response modifiers

12514 Background: As melanoma (MM) is an immunogenic tumor with poor response to chemotherapy immunomodulating agents are applied in order potentiate cytotoxic effect of and enhance antitumor immune response. Beside therapeutic benefit IFN-α IL-2, 13-cis retinoic acid (RA), as antiproliferative, differentiating agent also investigated. The these on NK cells, main innate system effectors, being Methods: 35 patients MM stage IV prior therapy 20 controls were We evaluated activity the expression activating (NKG2D CD161) inhibitory (CD158a CD158b) receptors freshly isolated PBL. Predicitive immunomodulation was performed 18 h vitro treated PBL rh IL-2 (200U/ml), IFN (250U/ml), RA (10 −6 M), their combination. Results: Native cell NKG2D CD161 fresh cells significantly decreased compared controls. Predictive treatments IFN, RA, unlike alone, gave a significant increase patients. Singly, induced no change CD158b, while decrease CD158a antigen. Evaluation mRNA transcription molecule IRF-1 shows that it promptly up-regulated by IFNα, more IFNα single has induction. Conclusions: Considering mechanism continually investigated optimize dose schedule administration and, also, considering controversial clinical results application, or this study we give novel show whereas, IFN-induced for first time associated CD16+NK not some receptors, regulated balance two types signals. No financial relationships disclose.